Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Livtencity
(United States) [Available]Synonyms :
maribavir
Class :
Antivirals
Brand Name :
Livtencity
(United States) [Available]Synonyms :
maribavir
Class :
Antivirals
Dosage Forms & Strengths
Tablet
200 mg
Take dose of 400 mg orally two times a day with or without meal
Dosage Modifications
Coadministration with anticonvulsants
Raise the dose up to 800 mg, twice a day and if carbamazepine is also being taken
Phenobarbital or phenytoin administered concurrently: the dosage be increased to 1200 mg twice a day
Renal impairment
Mild-to-severe: No dose adjustment necessary
End-stage renal disease: No study performed
Hepatic impairment
Mild-to-moderate: No dosage adjustment necessary
Severe: No study performed
Take dose of 400 mg orally two times a day with or without meal
Dosage Modifications
Coadministration with anticonvulsants
Raise the dose up to 800 mg, twice a day and if carbamazepine is also being taken
Phenobarbital or phenytoin administered concurrently: the dosage be increased to 1200 mg twice a day
Renal impairment
Mild-to-severe: No dose adjustment necessary
End-stage renal disease: No study performed
Hepatic impairment
Mild-to-moderate: No dosage adjustment necessary
Severe: No study performed
Dosage Forms & Strengths
Tablet
200 mg
Take dose of 400 mg orally twice a day with or without meal
Dosage Modifications
Coadministration with anticonvulsants
Raise the dose up to 800 mg, twice a day and if carbamazepine is also being taken
Phenobarbital or phenytoin administered concurrently: the dosage be increased to 1200 mg twice a day
Renal impairment
Mild-to-severe: No dose adjustment necessary
End-stage renal disease: No study performed
Hepatic impairment
Mild-to-moderate: No dose adjustment necessary
Severe: No study performed
Refer adult dosing
may decrease the levels of serum concentration of maribavir
may diminish the rate of excretion which could result in a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may decrease the therapeutic effect when combined with valganciclovir
may decrease the therapeutic effect when combined with ganciclovir-valganciclovir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of maribavir 
rifabutin: they may diminish the serum concentration of maribavir
Action
The viral UL97 protein kinase, which is necessary for CMV replication, is the target of maribavir’s activity. maribavir stops the virus from reproducing by impeding this enzyme, hence reducing the infection’s ability to propagate
Spectrum
maribavir’s therapeutic range is mainly dedicated to the management of CMV infections. For the treatment of CMV infections in transplant recipients who are resistant or refractory to conventional antiviral treatments, it has received FDA approval. maribavir has been demonstrated in clinical studies to be efficient in lowering the viral load and avoiding the recurrence of CMV infections.
Frequency defined
>10%
Disturbance of taste (46%)
1.5 to 2.5 mg/dL of creatinine (33%)
Hemoglobin between 8 and 9.5 g/dL (32%).
Nausea (21%)
Diarrhea (19%)
18% of platelets have a cell count of between 50,000 and 100,000.
Hemoglobin of between 6.5 and 8 g/dL (15%).
vomiting (14%).
Tiredness (12%)
Between 25,000 and 50,000 platelet cells per millilitre (12%)
1-10%
Creatinine >2.5 mg/dL (7%)
Platelet cell count <25,000 cells/µL (5%)
Neutrophils <500 cells/µL (2%)
Hemoglobin <6.5 g/dL (1%)
Neutrophils ≥750 to <1,000 cells/µL (4%)
Neutrophils ≥500 to <750 cells/µL (3%)
Black Box Warning:
maribavir has a black box warning because using medication while pregnant has the potential to result in birth abnormalities or harm to the foetus. maribavir is categorised as a Pregnancy Category X medicine, meaning there is evidence that it poses a risk to foetuses in humans and that it has been demonstrated to harm developing foetuses in animal tests.
The black box warning instructs medical professionals to inform patients about potential hazards and to use reliable contraception while receiving maribavir treatment and for at least 90 days following the final dose of the medication. Only if the benefits of using maribavir throughout pregnancy outweigh the hazards to the foetus should it be done.
Other important warnings and precautions for maribavir include the risk of neutropenia, thrombocytopenia , and renal impairment
Contraindication/Caution:
Â
Contraindication
maribavir should not be used during pregnancy since it may cause birth problems or harm to the foetus.
maribavir is prohibited for use with medications that are potent inducers or inhibitors of the CYP3A enzyme system because doing so may disrupt maribavir’s metabolism and raise the risk of adverse effects.
Caution
Breastfeeding: When giving maribavir to breastfeeding mothers, healthcare professionals should exercise caution because it is unknown whether the drug is excreted in breast mil
Renal impairment: maribavir has the potential to induce renal impairment, thus doctors should exercise caution when giving it to patients who already have renal impairment or who are taking other medications that may impair renal function
Neutropenia and thrombocytopenia: While taking maribavir, healthcare professionals should regularly check blood counts for neutropenia and thrombocytopenia
Use in immunocompromised patients: Medical professionals should exercise caution when administering maribavir to immunocompromised individuals due to the possibility of an increased risk of side effects. maribavir is primarily used to treat cytomegalovirus infections in these patients.
regnancy consideration:
Pregnancy category: NA
Lactation: The excretion of drug into human milk is unknown
Â
Pregnancy Categories:Â Â Â Â Â
Category A:Â Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C:Â there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D:Â adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X:Â Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N:Â There is no data available for the drug under this category
Pharmacology:
Human CMV enzyme pUL97’s competitive suppression of its protein kinase activity, which prevents protein phosphorylation, mediates antiviral action.
Pharmacodynamics:
maribavir’s primary pharmacodynamic effects stem from its suppression of the UL97 kinase enzyme. This suppression stops important viral proteins from being phosphorylated, which is necessary for viral replication and packaging. As a result, viral load and replication are both lowered.
Pharmacokinetics:
Absorption
maribavir is given orally and quickly absorbed from the digestive system. After consumption, peak plasma concentrations occur two to three hours later
Distribution
maribavir is widely circulating in the body and has the ability to pass the blood-brain barrier. With a 98% protein binding capability, the medication is strongly protein-bound.
Metabolism
The liver, specifically the cytochrome P450 (CYP) 3A enzyme system, is the primary site of maribavir metabolism. The primary metabolite of maribavir is M2, which is created when the parent substance is hydroxylated.
Elimination and Excretion
Around 75% of the medication is excreted unchanged in the urine after being removed largely by the kidneys. maribavir has a half-life of elimination of roughly 16 hours
Administration:
An oral drug called maribavir is normally taken twice daily with food. The tablets should not be chewed, crushed, or broken; they should be eaten whole with water
The recommended starting dose for adults is 400 mg twice daily, which may be adjusted based on the patient’s response to therapy and any adverse effects that may occur
Patient information leaflet
Generic Name: maribavir Â
Why do we use maribavir?
maribavir is indicated for the treatment of cytomegalovirus infections in transplant recipients who are resistant or refractory to other antiviral therapies. The drug has been shown to be effective in reducing the viral load and preventing the recurrence of CMV infections
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
